Apixaban: Alternative Anticoagulation for HeartMate 3 Ventricular Assist Device

Area of Science:

• Cardiology
• Medical Devices
• Pharmacology

Background:

• Patients with left ventricular assist devices (LVADs) require long-term anticoagulation, typically with warfarin.
• Warfarin necessitates frequent monitoring and carries risks of adverse events if outside the therapeutic range.
• Apixaban presents a potential alternative with improved compliance and no need for routine testing.

Purpose of the Study:

• To compare the safety and adverse events of apixaban versus warfarin in patients with a HeartMate 3 LVAD.
• To evaluate rates of stroke, bleeding, and death in patients receiving either anticoagulant therapy.

Main Methods:

• A retrospective study of 35 patients who underwent HeartMate 3 LVAD implantation between January 2016 and January 2021.
• Patients were divided into two groups: apixaban (n=15) and warfarin (n=20), all receiving daily aspirin.
• Primary outcomes included stroke, bleeding, and death, analyzed using univariate nonparametric statistics.

Main Results:

• No significant difference in thrombotic complications or death at 6 months between apixaban and warfarin groups.
• The apixaban group showed clinically lower rates of bleeding complications (5% vs. 30%).
• Deaths in the apixaban group were attributed to right heart failure; no significant difference in overall adverse events was observed.

Conclusions:

• Apixaban appears to be a safe alternative anticoagulant therapy for patients with HeartMate 3 LVADs.
• The study suggests similar rates of major adverse events (bleeding, stroke, death) between apixaban and warfarin in this patient population.
• Apixaban may offer benefits in terms of compliance and reduced monitoring needs for LVAD patients.